Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors.

Autor: Vernet R; Centre for Translational Research in Onco-Hematology, University of Geneva, Geneva, Switzerland.; Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland., Fernandez E; Department of Oncology, Geneva University Hospitals and Medical School, Geneva, Switzerland.; Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland., Migliorini D; Department of Oncology, Geneva University Hospitals and Medical School, Geneva, Switzerland.; Centre for Translational Research in Onco-Hematology, University of Geneva, Geneva, Switzerland.; Agora Cancer Research Center, Lausanne, Switzerland.; Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland., Ancrenaz V; Department of Oncology, Geneva University Hospitals and Medical School, Geneva, Switzerland.; Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland., Charrier E; Centre for Translational Research in Onco-Hematology, University of Geneva, Geneva, Switzerland.; Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland.; MaxiVAX SA, Geneva, Switzerland., Belkouch MC; Centre for Translational Research in Onco-Hematology, University of Geneva, Geneva, Switzerland.; Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland., Von Rohr O; Centre for Translational Research in Onco-Hematology, University of Geneva, Geneva, Switzerland.; Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland., Urwyler M; Centre for Translational Research in Onco-Hematology, University of Geneva, Geneva, Switzerland.; Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland., De Vito C; Division of Clinical Pathology, Diagnostic Department, Geneva University Hospitals, Geneva, Switzerland., Renaux J; MaxiVAX SA, Geneva, Switzerland., Villard J; Clinical Cell Therapy Lab, Geneva University Hospital, Geneva, Switzerland., Rubin O; Clinical Cell Therapy Lab, Geneva University Hospital, Geneva, Switzerland., Grogg J; MaxiVAX SA, Geneva, Switzerland., Mach N; Department of Oncology, Geneva University Hospitals and Medical School, Geneva, Switzerland.; Centre for Translational Research in Onco-Hematology, University of Geneva, Geneva, Switzerland.; Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland.

Publikováno v: Cancer research communications [Cancer Res Commun] 2024 Aug 01; Vol. 4 (8), pp. 2089-2100.

Immortalized human myoblast cell lines for the delivery of therapeutic proteins using encapsulated cell technology.

Autor: Lathuiliere A; Oncology Division, Geneva University Hospital and Medical School, 1211 Geneva, Switzerland., Vernet R; Oncology Division, Geneva University Hospital and Medical School, 1211 Geneva, Switzerland.; Centre for Translational Research in Onco-Hematology, Oncology Division, Geneva University Hospital and University of Geneva, 1211 Geneva, Switzerland., Charrier E; Oncology Division, Geneva University Hospital and Medical School, 1211 Geneva, Switzerland.; Centre for Translational Research in Onco-Hematology, Oncology Division, Geneva University Hospital and University of Geneva, 1211 Geneva, Switzerland.; MaxiVAX SA, 1202 Geneva, Switzerland., Urwyler M; Oncology Division, Geneva University Hospital and Medical School, 1211 Geneva, Switzerland.; Centre for Translational Research in Onco-Hematology, Oncology Division, Geneva University Hospital and University of Geneva, 1211 Geneva, Switzerland., Von Rohr O; Oncology Division, Geneva University Hospital and Medical School, 1211 Geneva, Switzerland.; Centre for Translational Research in Onco-Hematology, Oncology Division, Geneva University Hospital and University of Geneva, 1211 Geneva, Switzerland., Belkouch MC; Oncology Division, Geneva University Hospital and Medical School, 1211 Geneva, Switzerland.; Centre for Translational Research in Onco-Hematology, Oncology Division, Geneva University Hospital and University of Geneva, 1211 Geneva, Switzerland., Saingier V; Oncology Division, Geneva University Hospital and Medical School, 1211 Geneva, Switzerland.; Centre for Translational Research in Onco-Hematology, Oncology Division, Geneva University Hospital and University of Geneva, 1211 Geneva, Switzerland., Bouvarel T; Institute of Pharmaceutical Sciences of Western Switzerland (ISPSO), University of Geneva, 1211 Geneva, Switzerland.; School of Pharmaceutical Sciences, University of Geneva, 1211 Geneva, Switzerland., Guillarme D; Institute of Pharmaceutical Sciences of Western Switzerland (ISPSO), University of Geneva, 1211 Geneva, Switzerland.; School of Pharmaceutical Sciences, University of Geneva, 1211 Geneva, Switzerland., Engel A; MaxiVAX SA, 1202 Geneva, Switzerland., Salmon P; Department of Basic Neurosciences, University of Geneva, 1211 Geneva, Switzerland., Laumonier T; Cell Therapy and Musculoskeletal Disorders Laboratory, Department of Orthopaedic Surgery, Faculty of Medicine, Geneva University Hospital and University of Geneva, 1211 Geneva, Switzerland., Grogg J; MaxiVAX SA, 1202 Geneva, Switzerland., Mach N; Oncology Division, Geneva University Hospital and Medical School, 1211 Geneva, Switzerland.; Centre for Translational Research in Onco-Hematology, Oncology Division, Geneva University Hospital and University of Geneva, 1211 Geneva, Switzerland.

Publikováno v: Molecular therapy. Methods & clinical development [Mol Ther Methods Clin Dev] 2022 Aug 01; Vol. 26, pp. 441-458. Date of Electronic Publication: 2022 Aug 01 (Print Publication: 2022).

B7-homolog 1 expression by human glioma: a new mechanism of immune evasion.

Autor: Wilmotte R; Laboratory of Tumor Immunology, Division of Oncology, University Hospital Geneva, Geneva, Switzerland., Burkhardt K, Kindler V, Belkouch MC, Dussex G, Tribolet Nd, Walker PR, Dietrich PY

Publikováno v: Neuroreport [Neuroreport] 2005 Jul 13; Vol. 16 (10), pp. 1081-5.